Stock KAN KANCERA AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Kancera AB

Equities

KAN

SE0015658570

Delayed Nasdaq Stockholm
Other stock markets
 02:24:51 07/05/2024 pm IST 		5-day change 1st Jan Change
1.452 SEK +0.14% Intraday chart for Kancera AB -1.22% -68.05%
03/05 Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects CI
23/02 Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023
Kancera AB Signs A License Agreement with the University of Newcastle
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study
Kancera AB Reports Positive Top Line Results from the FRACTAL Study
Kancera AB Provides Operational Update Regarding Fractalkine Block Blockers KAN567 and KAND145
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Kancera AB Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145
Kancera Names Successor to Outgoing Chief Medical Officer
Kancera AB Appoints Markus Jerling as Chief Medical Officer
Kancera AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Kancera AB Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease
Kancera AB Reports Dosing of First Patient in the KANDOVA Study
Kancera AB Appoints Thomas Olin as Executive Vice President and Chief Scientific Officer
Kancera AB Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023
Kancera AB Reports Earnings Results for the First Quarter Ended March 31, 2023
Kancera AB Submits Application to Conduct First-In-Human Study of Kand145
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KAN Stock
  4. News Kancera AB
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW